YL93

Cat. No.:	HY-146806
CAS No.:	2771313-42-7
Molecular Formula:	$C_{37}H_{38}Cl_2F_2N_4O_4$
Molecular Weight:	711.62
Target:	MDM-2/p53
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

YL93 is a dual inhibitors of MDM2/4 with K_i values of 0.64 μM and 1.1 nM for MDM4 and MDM2, respectively. YL93 induces cell-cycle arrest and apoptosis. YL93 shows p53-dependent cell growth inhibition[1].

In Vitro

YL93 shows anti-tumor activity and inhibits HCT-116 cell growth with an IC_{50} value of 50.7 nM[1].
YL93 (0.078-2.5 μM; 24 h) increases the protein level of p53, p21, MDM2[1].
YL93 (0.02-2.5 μM; 24 h) arrests cell cycle at G1[1].
YL93 (6.25-25 μM; 48 h) increases apoptotic RKO cells[1].
YL93 (2.5 μM; 48 h) increases transcription of p53-targeted genes, MDM2, p21, and PUMA in MDM4-overexpressing cell lines H460, MCF-7, and U-2 OS[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	HCT-116 cells
Concentration:	0.078125 μM, 0.15625 μM, 0.3125 μM, 0.625 μM, 1.25 μM, and 2.5 μM
Incubation Time:	24 hours
Result:	Significantly increased the protein level of p53, p21, MDM2.

Cell Cycle Analysis[1]

Cell Line:	HCT-116 cells
Concentration:	0.02 μM, 0.1 μM, 0.5 μM, 2.5 μM
Incubation Time:	24 hours
Result:	Arrested cell cycle at G1 phase.

REFERENCES

[1]. Zhang S, et al. Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells. J Med Chem. 2022 Apr

28;65(8):6207-6230.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA